New hope for Hard-to-Treat hormone cancers: experimental drug shows promise
NCT ID NCT01273168
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This early-phase trial tested an experimental drug called Z-Endoxifen in 40 adults with hormone receptor-positive cancers (like breast, ovarian, or desmoid tumors) that had stopped responding to standard treatments. The drug works by blocking estrogen from fueling cancer growth, similar to tamoxifen but without needing the liver to activate it. The main goal was to check safety and find the right dose, while also seeing if it could slow tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.